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Pulmonaryemboli are frequent causes of morbidity and mortality in patients with brain tumors.Treatment options are limited in
these complex patients. We report a case of successful acute pulmonary embolectomy in a patient with an advanced brain cancer.
1.Introduction
Patients with cancers, particularly brain, are at considerable
risk for deep vein thrombosis (DVT) and pulmonary
embolism (PE). Twenty-six percent of patients with high
grade gliomas developed DVTs, and 15% PEs, within 12
months of treatment [1]. Larger and more symptomatic
PE’s are often treated with thrombolytics, however surgical
indications are expanding. Thrombolytics or high-dose
anticoagulation for cardiopulmonary bypass is typically
contraindicated in patients with signiﬁcant intracranial
pathology [2]. Our favorable surgical management of a
patient with a postinfarct ventricular septal defect and acute
intracranial hemorrhage [3] has prompted us to consider
pulmonary embolectomy to patients with known brain
cancers who develop massive PEs.
Our patient is 47 years old, ﬁrst diagnosed with a right
temporal lobe Glioblastoma multiforme (GBM) in 2005 that
was treated with surgical resection and reoperation in 2007
and 2008. He continued to receive cycles of chemotherapy
and local irradiation for disease recurrence. He had mild
right-sided weakness, short-term memory, and cognitive
defectsbutwas functional and living at home. In 02/2009,he
developed acute shortness of breath and chest CT conﬁrmed
a large saddle pulmonary embolism (Figure 1). He was
hemodynamically stable and anticoagulated with a weight-
based heparin protocol. Despite adequate anticoagulation,
he became fatigued and hypoxemic (O2 saturation: 90%
on 3 liters via cannula). A transthoracic echocardiogram
showed reduced global right ventricular function and his
B-type Natriuretic Factor was elevated at 212pg/mL. His
Troponin was 0.14ng/mL (normal < 0.11). His heart rate
was 105bpm and respiratory rate was >20/min and he felt
short of breath sitting up and could not lie ﬂat. Because of
his brain tumor, based upon established guidelines for the
management of PE, thrombolytic therapy was felt to be an
absolute contraindication [2]. Because of his anatomically
large PE and worsening clinical picture, surgical therapy
was oﬀered. Median sternotomy was performed, cardiopul-
monary bypass was initiated with full heparinization (goal
activated clotting time >350 seconds), the aorta was cross-
clamped and the heart was arrested. The main pulmonary
artery was opened and large emboli were extracted from the
main and left pulmonary artery and lobar branches. The
right pulmonary artery was exposed between the superior
vena cava and the aorta and addition clots were extracted
manually and with a small suction catheter. The pulmonary
arteries were irrigated clean with heparinized saline. Total2 Case Reports in Medicine
Figure 1: CT pulmonary angiogram showing a large saddle
embolus.
bypass time was 40 minutes and the cross-clamp time was
30 minutes. Immediately postoperatively an IVC ﬁlter was
placed. He was extubated within 24 hours. His neurologic
function was unchanged and postoperative course was
unremarkable. Venous duplex scanning showed extensive
clot in both legs and systemic anticoagulation with heparin
was started 12hrs postoperatively. He was discharged to a
rehabilitation facility, on room air and sodium warfarin,
on postoperative day 8. Two weeks later, he returned home
and at 6 weeks a repeat MRI showed no disease progression
(Figure 2). He survived for 12 additional months at home
before returning with an overwhelming infection and septic
shock at which time support was withdrawn.
2.Discussion
Surgical management of massive PEs is an acceptable
therapy. For example, Kadner recently reported a 30-day
mortality of 8% following salvage pulmonary embolectomy
[4]. Of note, 1 of the 2 deaths was from intracerebral
bleeding. In their experience, most patients had signiﬁcant
hemodynamic compromise (32% had a preoperative arrest)
and 16% had a cancer.
But, the management of patients with massive PEs and
an intracranial process can be challenging. Such patients are
at risk for dying from shock or acute right heart failure.
Therapies must be balanced against the risk of worsening
or precipitating an intracranial bleed. A recent report with
thrombolytic therapy in a patient with a PE and a brain
tumorarguesthe <10%risk forhemorrhagic transformation
must be balanced against the 25–100% case fatality rate for
massive PEs [5]. However, there is little additional data to
support this practice.
Another treatment option is catheter directed therapy—
even in patients with contraindications to systemic throm-
bolytic therapy. These techniques involve direct mechanical
fragmentation, aspiration, or direct thrombolytic therapy
a n dh a v eb e e ns h o w nt ob ee ﬀective and safe in patients
with massive PE [6]. These techniques, when successful,
are associated with a quick resolution of symptoms and
hemodynamic instability can often be accomplished quickly.
However, there is a lack of standardized protocols and no
Figure 2: MRI of the brain, 6 weeks after embolectomy, showing
stable disease.
device or catheter has an approved indication by the United
States Food and Drug Administration (FDA) for the treat-
ment of pulmonary embolism. Likewise, no thrombolytic
agent has FDA approval for direct pulmonary infusion.
Nevertheless, recent guidelines describing the management
of PE suggest that catheter-directed therapy can be an
acceptable option for the treatment of massive PE and
can potentially serve a life-saving role in an institutional
management algorithm [2].
Cardiac surgery, because of presumed bleeding risks
has been historically contraindicated in patients with severe
intracranial pathology. Our recent experience [3]a n d
Fukuda’s report of 3 successful cases of salvage pulmonary
embolectomy in patients with recent intracranial bleeding
[7] contribute to the rationale of operating on these acutely
ill patients—particularly in whom full anticoagulation with
heparin for bypass might be theoretically less harmful than
systemic lytic therapy.
Our case demonstrates the feasibility of extending the
surgical management of massive PEs to patients with
advanced brain cancers. While such interventions may be
considered aggressive or futile in neurologically debili-
tated patients with known life-limiting medical problems,
our experience suggests the contrary. Preoperative neuro-
oncology consultation, projected a 6–12 months, albeit
unpredictable, survival. In addition, this experience also
emphasize the need for open communication, particularly
with a Palliative Care team, and a reasonable set of expec-





traditionally considered at prohibitive risk or in whom
thrombolytics are contraindicated. Our cases demonstrateCase Reports in Medicine 3
that pulmonary embolectomy can be successful in patients
withadvancedbraintumors.Ourexperiencealsoemphasizes
that in each case, regardless of the comorbidities and man-
agement plan, that there needs to be careful consideration
given to the patient’s baseline and anticipated functional
status, expected duration of survival, and most importantly,
any known advances directives. In some centers, depending
on team preferences and skills, catheter-based therapies may
be an acceptable alternative to surgical options. While we
advocate—based upon our experiences—surgical manage-
ment, regardless of the preferred approach, an institutional
algorithm for the treatment of massive PE should include
patients who have contraindications to thrombolytic ther-
apy.
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